PRF-110 Preclinical Study Shows 72-Hour Pain Relief Comparable to Approved Benchmark
PRFX is trading near its 52-week low of $1.28 (12% above the low) on light trading volume (0.2× avg).
Summary
PRF Technologies announced positive preclinical results for its lead product candidate, PRF-110, demonstrating sustained 72-hour analgesic activity comparable to the approved benchmark ZYNRELEF. PRF-110's ropivacaine-only, NSAID-free formulation also suggests a potential safety advantage with lower cardiac toxicity. This positive pipeline development is significant for the micro-cap company, especially following recent highly dilutive equity financing agreements in May. The results de-risk future development steps and could bolster investor confidence.
At the time of this announcement, PRFX was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $1.28 to $17.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.